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to antibiotics with greater accuracy and speed; as molecular diagnostics can be carried out directly on the biopsy without the need for culturing. [7] Molecular detection of clarithromycin resistance among H. pylori strains is mostly based on analysis of the unique point mutations in 23S rRNA gene; the most common mutations associated with resistance being transitions and transversions at positions 2142/43 (A2142G and A2143G). Available methods to study these mutations include direct sequencing, polymerase chain reaction (PCR), PCR-restriction fragment length polymorphism (PCR-RFLP), real-time PCR assays, microelectronic chip array and fluorescent in situ hybridisation. [8] Resistance of H. pylori to fluoroquinolones caused by point mutations in the so-called quinolone resistance-determining regions (QRDRs) of the gyrA gene of H. pylori can be studied by PCR-RFLP analysis, allele-specific PCR, single-strand conformational polymorphism analysis, oligonucleotide ligation assay and real-time PCR. [9] Tetracycline resistance in H. pylori mostly associated with mutations in the 16S rRNA genes has been studied by PCR-RFLP, real-time PCR [5] and sequencing. [10] In H. pylori, metronidazole resistance is primarily associated with mutational inactivation of the oxygen-insensitive NADPH nitroreductase, rdxA gene, [11] one of these inactivation mechanisms being a deletion in rdxA gene. [12] Resistance has been studied by PCR; however, as many mutations are involved, it is not applicable for routine purposes. [5] The present study was undertaken to determine the primary antibiotic resistance in H. pylori in a tertiary care hospital, by studying common mutations leading to resistance to clarithromycin, quinolones, tetracycline and metronidazole using PCR-based molecular methods.
matErials anD mEtHODs
This study conducted over a period of 20 months starting from January 2014 was a collaboration between the Departments of Gastroenterology, Microbiology and Pathology of our Institute and was approved by the Institutional Ethics Committee.
Eligibility criteria
This cross-sectional study was conducted on 196 adult patients with dyspepsia, independently found to have clinical indications for an endoscopy at the outpatient gastrointestinal clinic of our hospital. Patients were enrolled in the study after informed consent to undergo testing of endoscopy samples with details of history and physical examination recorded in data collection forms. Six biopsy specimens were taken, three each from the antrum and body of the stomach and subjected to three diagnostic tests namely histopathological examination (HPE), rapid urease test (RUT) and culture. Each test was conducted on two biopsy samples, one each from antrum and body.
Exclusion criteria
Patients <18 years old, a history of proton pump inhibitor intake within 2 weeks, H 2 antagonists within 1 week and antibiotic intake within 1 month prior to inclusion in the study were excluded from the study.
Inclusion criteria
A patient with H. pylori infection was defined as one independently assessed by the attending clinician on the basis of clinical symptoms and a positive test for any of the two diagnostic tests (HPE and RUT). For drug susceptibility testing (DST) by molecular methods, a biopsy with positive RUT or a culture isolate or both were included. A positive RUT increased the likelihood that the specimen would contain a sufficient number of bacterial cells and decreased the chances of false-negative results. [8] All the patients underwent three tests for detection of H. pylori infection (RUT, HPE and culture). Further, fifty randomly selected RUT-positive biopsies and culture isolates were subjected to PCR for glmM gene. 60 glmM gene-positive samples (47 RUT-positive biopsies and 13 H. pylori isolates) were subjected to mutational analysis for resistance detection.
Histopathology
Biopsy specimens in 10% formaldehyde were stained with Giemsa and haematoxylin and eosin dye. A specimen was read as positive if curved bacilli were seen on microscopy.
Rapid urease test
It was performed in 0.5 ml of 8% (weight/vol.) unbuffered urea in distilled water (pH 6.8) in a transparent 0.7-ml Eppendorf tube (stored at 4°C) to which one drop of 1% phenol red (free acid) suspension was added on the day of use to ensure colour stability. Biopsy specimens were placed in the tube and a positive test was indicated by a rapid colour change of the media surrounding the biopsy from yellow to magenta followed by a rapid generalised colour change throughout the media. A negative result was indicated by no change in colour up to 2 h of observation. [13] Specimens with positive RUT were kept at −20°C for subsequent DNA extraction.
Culture
Specimens for culture were taken before specimens for HPE to avoid transferring small amounts of fixative to the container for biopsy specimens to be used for culture. Two biopsy specimens were placed in 0.6-mL BBL™ Brucella broth (Becton, Dickinson and Company, USA) containing 25% glycerol [14] and frozen at −70°C until culture. [15] Only those biopsies that were RUT and/or HPE positive were processed for culture.
The biopsy specimens after thawing were vortexed for 2 min and 200 µl of the mixture was plated on Petri plates containing Brucella agar (Becton, Dickinson and Company, USA) with 5% defibrinated sheep blood and Campylobacter supplement-III [13] from HiMedia Labs, India (trimethoprim 5 mg/L, vancomycin 10 mg/L and polymyxin B 2500 units/L). Plates were incubated at 37°C for 10 days in a microaerophilic (5% O 2 , 10% CO 2 and 85% N 2 ) environment using CampyGen microaerophilic gas packs, Mitsubishi Gas Chemical Co., Inc. Tokyo Japan (Cat No. 0035A) placed in polypropylene jars (Hi Media Labs, Mumbai, India).
The plates were first examined on the 5 th day. H. pylori colonies were typically small, flat and translucent to grey. On day 5, all plates with no characteristic colonies were incubated for an additional 5 days before reporting a negative growth. The presence of H. pylori was indicated by Gram-negative curved bacilli and a positive test for urease, oxidase and catalase production. [13] The H. pylori strains were preserved in sterile Brucella broth containing 20% glycerol at −70°C till further processing. [14] DNA extraction DNA was extracted from RUT-positive gastric biopsies and culture isolates kept at −20°C using Zymo Research Quick-g DNA Mini Prep, Epigenetics company, USA (Catalogue No. D3024) and from isolates kept at −70°C using GeneJET genomic DNA purification kit from Thermo Fisher Scientific, Noida, India (Catalogue No. K0721) according to the manufacturer's instructions. The extracted DNA was stored at −20°C until use. It was first subjected to PCR for housekeeping gene; glmM (ureC) for confirmation of H. pylori. [16] All the primers were synthesised by Integrated DNA Technologies, Gurgaon, India except glmM gene which was synthesised by Sigma-Aldrich Inc., New Delhi, India. Amplification of DNA was performed in a thermal cycler Applied Biosystem 2720, Thermo Fisher Scientific, India.
Detection of glmM (ureC) gene
The presence of H. pylori was confirmed by detection of glmM gene by PCR, using primers and protocol, [16] as summarised in Table 1 .
Drug susceptibility testing in Helicobacter pylori
For detecting resistance to metronidazole, clarithromycin, quinolones and tetracycline, sixty samples positive for glmM gene were subjected to the following PCR methods.
PCR of rdxA gene for metronidazole resistance
Primers [ Table 1 ] used were those designed to amplify 850-bp amplicon designating wild-type rdxA gene of H. pylori and/ or a 650 bp amplicon indicating the presence of mutation in rdxA gene, leading to metronidazole resistance. [17] A missing wild-type gene was also considered as resistance. Reaction mixture and PCR conditions were same as for glmM [ Figure 1 ].
PCR of gyrA and gyrB genes for fluoroquinolone resistance
Primers used were those designed to amplify gyr A and gyr B genes [6] as per the protocol [ Table 1 ]; absence of either of the two bands suggested mutation leading to quinolone resistance [ Figure 2 ].
Allele-specific primer-PCR of the 23S rRNA for clarithromycin resistance
Allele-specific primer-PCR for the detection of the 23S rRNA gene mutations, A2142G and A2143G, was performed [ Table 1 ]. [18] The 320 bp fragment indicates the presence of the wild-type H. pylori 23S rRNA gene, while 238 bp and 118 bp fragments indicate the presence of mutations A2142G and A2143G, respectively, which cause clarithromycin resistance [ Figure 3 ].
PCR-RFLP of 16S rRNA gene to study tetracycline resistance
Primers [ Table 1 ] used were those designed to amplify the conserved 535 bp region of the H. pylori 16S rRNA gene between nucleotide positions 710 and 1245 [ Figure 4 ]. [10, 19] RFLP of the 535 bp PCR products thus obtained was done using restriction enzyme HinfI. Tetracycline-susceptible H. pylori clinical isolates with a single HinfI (5'-G ↓ ATTC-3') cleavage site within the conserved 535 bp region generate 254 and 281 bp HinfI digestion products, while mutant strains with high-level tetracycline resistance carrying the AGA926-928 → TTC substitution in both copies of the 16S rRNA genes display an additional HinfI restriction site in the conserved 535 bp region, thus generating 40, 214 and 281 bp HinfI digestion products. [10] 5 µl of restriction digestion product was loaded onto 3.5% agarose gel, run in tris acetate EDTA (TAE) buffer for 1.5 h at 90 V and viewed in the Gel Documentation system (Alpha Imager, California, USA). The size of the DNA restriction fragments 
Antibiotic resistance pattern in Helicobacter pylori
Of the 60 samples included for DST, 58 belonged to each of the 58 patients, while the two extra samples belonged to two patients whose biopsy and cultures were positive. Overall, maximum resistance was seen to metronidazole (81.66%) followed by clarithromycin (45%) and quinolones (3.33%).
No high-level resistance was seen to tetracycline. Resistance was seen more in biopsy samples than in isolates [ Table 2 ].
Multidrug resistance
Multidrug resistance (MDR) means that a strain is resistant to two or more classes of antibiotics. Combined resistance to metronidazole and clarithromycin was seen in 41.66% of the samples tested, with more resistance (38.33%) seen in biopsy samples than in isolates (15.38%).
Statistical analysis
Demographic and resistance data were described using rates and percentages for categorical variables.
DiscussiOn
In our study, we used glmM gene PCR for confirmation of H. pylori in both RUT-positive biopsies and culture isolates [19] followed by DST by molecular methods. [8, 20] Biopsies for RUT, both in liquid form stored at −20°C as in the present study and gel form stored at room temperature, [15] can be put to double use with no need for additional sampling.
H. pylori like Mycobacterium tuberculosis acquires resistance by mutation concerning all of the antibiotics proposed in eradication regimens. The mechanism does not involve plasmids which could be transmitted horizontally but point mutations which are transmitted vertically, while transformation may be possible if two strains are present simultaneously in the stomach. The consequence is a progressive increase in the resistance rate due to the selection pressure. [21] In the present study, we detected the two most prevalent point mutations: A2143G and A2142G in 23S rRNA gene associated with clarithromycin resistance of H. pylori strains using allele-specific primer-PCR in both biopsy samples and isolates. This method is rapid and cheap as compared to the commonly used PCR-RFLP method. [22] Other less common mutations were not sought in our study.
Overall resistance to clarithromycin in our study was 45% [ Table 2 ]. Higher resistance of 58.8% and 76% has been reported from central Gujarat (2014) and South India (2012), [23, 24] [25, 26] Since macrolide antibiotics show cross resistance, the higher clarithromycin resistance rates could be attributed to indiscriminate use of erythromycin and azithromycin in our population for respiratory infections. Of the 27 resistant strains in our study, 59.25% carried A2142G mutation and 40.74% carried A2143G mutation, with one strain carrying both the mutations [ Table 2 ].
The most common mutation worldwide is A2143G that occurred in about 69.8% of strains resistant to clarithromycin, but its prevalence varied from 52.7% in Germany up to 95.6% in Hong Kong. [27] The average prevalence of A2142G mutation amounted to 11.7% and ranged from 5% of the resistant strains in Iran to 66.6% in Japan, [27] similar to that observed in our study. Klesiewicz et al. in 2014 [28] observed an equal prevalence of both mutations in all the analysed strains, while we in our study observed higher prevalence of A2142G mutation. A higher prevalence of A2142G mutation is alarming as it has been associated with higher minimum inhibitory concentration values as compared to A2143G. [28] The prevalence of resistance to metronidazole in H. pylori has been reported to range between 8% and 80% in different countries. [29] The trend seen in India is all the more alarming with a resistance rate of 83.85% and 100% reported from Gujarat (2014) and South India (2012), respectively. [23, 24] In our study, of the 60 samples, 49 (81.66%) showed the 650 bp band suggestive of mutation in the rdxA gene (200 bp deletion) and metronidazole resistance [ Table 2 ]. A significant correlation between rdxA gene deletion and metronidazole resistance has been reported by Abdollahi et al. [17] Resistance to metronidazole in our study was quite high which could be even higher as 200 bp deletion in rdxA gene is not the only mechanism of resistance to H. pylori. Other mechanisms involved may be rdxA gene inactivation by insertion of a transposon called Mini-IS605 [30] and inactivation of the frxA gene either alone or in association with the rdxA gene. [31, 32] In most of the samples that tested resistant to clarithromycin and metronidazole, a mixed population of wild and mutant strains was present, more so in biopsies than in the culture isolates. This was more prominent in metronidazole [ Table 2 ].
In India, in a study by Patra et al., almost all infected cases were found to carry multiple H. pylori strains. This heterogeneity of H. pylori population is clinically very important as the existing practice of characterisation of a single isolated colony from infected individuals may oversight the appropriate target of virulence gene or its allele. This strengthens the view of including multiple colonies from a single host. [14] In our study, for DNA extraction, we picked single colonies from cultures while two biopsy samples from antrum and body of the stomach were used. This could have been the reason for In our study, combined resistance to metronidazole and clarithromycin (MDR) was seen in 41.66% of the samples tested. High resistance of 57.5% in H. pylori strains to metronidazole and clarithromycin from Gujarat, India, [23] and a low prevalence of MDR of 11% have been reported from Saudi Arabia. [25] The high prevalence of MDR could be due to the frequent use of these antibiotics to treat other infections and an ineffective local drug control policy. Another possibility could be the simultaneous infection with different strains of H. pylori. [24] Resistance to fluoroquinolones is generally very low (<10%) worldwide. [33] Mutations in the QRDRs of the gyrA gene have been found to be linked to fluoroquinolone resistance in H. pylori. Mutations in the gyrB gene have also been reported in levofloxacin-resistant strains isolated in Japan, but these often occurred along with gyrA mutations. [6] In our study, of the sixty samples tested by PCR for gyrA and gyrB genes, 58 showed the presence of both bands corresponding to the two genes. Thus, resistance by this method amounted to just 3.33%. In two of our samples, both gyrA and gyrB bands were absent. The reason for low resistance in our study could be that all point mutations in the QRDR of the gyrA and gyrB gene do not result in an absent band for which either allele-specific PCR or sequencing of the amplified products of gyrA and gyrB genes is needed to detect point mutations related to quinolone resistance. It was not feasible to perform such technique in this study.
Tetracycline is an antibiotic that is frequently used in several second-line regimens for H. pylori infection. [34, 35] Besides its wide availability, until recently, resistance of H. pylori to this antimicrobial drug was rare. It was reported to be <2% in most studies across the globe. [13, 26, 29] In India, a resistance of 4% was reported from South India in 2012, [24] while a very high resistance of 53.8% had been reported from Gujarat in 2014. [23] High-level tetracycline resistance in H. pylori is a serious concern as it negatively affects the efficacy of tetracycline-containing regimens. [35, 36] In our study, we did not find any high-level resistance to tetracycline; however, low-level resistance cannot be ruled out; whenever a 'tetracycline-susceptible phenotype' is obtained by PCR-RFLP/HinfI method used in our study, sequencing of the 535 bp fragment is required either to validate the observation or to identify eventual single or double substitutions at nucleotides 926-928, which may sustain a low-level tetracycline-resistant phenotype. [10] Since other mechanisms of resistance to various antibiotics may also be involved, complementary culture and susceptibility testing to assess H. pylori resistance are still necessary.
Limitations of our study
Our study is not without caveats. First, resistance testing in H. pylori by molecular methods is evolving; multiple mechanisms have been attributed to resistance and no single molecular method is enough to study resistance. Thus, resistance rates to various antibiotics reported in our study may not be 100% accurate. Second, all mutations may not be phenotypically expressed. To overcome this, many studies across the globe have done molecular analysis of resistance in phenotypically resistant isolates. In our study, we attempted DST of our isolates by E-test method, but because of problems of high fungal contamination and failure to get good growth which is a prerequisite for testing by this method, it was abandoned and we switched over to genotypic methods instead.
cOnclusiOns
Although molecular methods offer an attractive alternative technique to phenotypic methods of DST in H. pylori, culture susceptibility testing is a necessary adjunct in the study of drug resistance in this pathogen.
Tetracycline and quinolones could be the antibiotics of choice in the eradication of H. pylori in our region. With a high resistance rate to metronidazole and clarithromycin, recurrence of the infection with H. pylori could be expected among patients receiving either of the two drugs for eradication therapy. Hence, regimens containing these drugs should be prescribed only after primary DST for H. pylori.
